Market Overview:
The global antibody drugs market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, rising demand for targeted therapies, and technological advancements in the field of antibody drug development. Based on type, the global antibody drugs market is segmented into monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and polyclonal antibodies (PCAs). mAbs are expected to account for the largest share of this market in 2018. This segment is projected to grow at a CAGR of 11.1% during the forecast period from 2018 to 2030. The large share and high growth rate for this segment can be attributed to factors such as rising demand for personalized therapies and increasing R&D investments by biopharmaceutical companies in mAb therapeutics. Based on application, the global antibody drugs market is divided into central nervous system disorders (CNS disorders), cancers, autoimmune disorders, and cardiovascular diseases. CNS disorders are estimated to account for the largest share of this market in 2018 followed by cancers and autoimmune disorders respectively.
Product Definition:
Antibody drugs are a type of biologic drug used to treat autoimmune diseases, cancer and other conditions. They are made from human or animal antibodies that identify and neutralize specific proteins on the surface of cells.
Monoclonal Antibodies:
Monoclonal antibodies are antibody molecules, which are manufactured by the human body specifically targeting a specific disease-causing cell. There is an increase in demand for monoclonal antibodies due to their ability to target cancer cells and destroy them without harming surrounding tissues or organs. Monoclonal Antibodies can also be used in Cancer Immunotherapy, where it targets the immune system so that it attacks cancer cells without affecting other normal body functions.
Antibody-Drug Conjugates:
Antibody-drug conjugates (ADC) are a group of drugs that bind to an antibody and target cell. The drug is linked with an antibody by means of a linker, which is usually made up of amino acids. There are two types of ADC: those that use the enzyme puromycinase for linking the drug to the antibody, and those that use cholera toxin B as a linker.
Application Insights:
The central nervous system disorders segment dominated the global market in 2017. This is attributed to the presence of a strong pipeline and high prevalence of neurological disorders. For instance, there are over 100 million people suffering from Parkinson¢â‚¬â„¢s disease worldwide which represents a lucrative opportunity for drug manufacturers. Monoclonal antibodies against dopamine receptor D2 are currently in phase III clinical trials and expected to be available for prescription soon; these drugs can treat both levodopa-induced motor symptoms as well as cognitive impairment caused by Parkinson¢â‚¬â„¢s disease (PD).
Cancer is another major application segment due to increasing cancer cases globally coupled with rising demand for effective treatment options. According to WHO, an estimated 1 in 6 women and 1 in 5 men will develop cancer during their lifetime; this amounts to 2 billion people being diagnosed with the disease annually worldwide.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of biotechnology and pharmaceutical companies, advanced healthcare infrastructure, high disposable income, and favorable reimbursement policies are some factors driving the regional market. In addition, increasing investments by governments for R&D activities to create new therapies is also expected to drive growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising healthcare expenditure by governments as well as private organizations in order to improve treatment options for patients across this region. Moreover, growing awareness about various diseases coupled with improving healthcare facilities will boost demand further over coming years.
Growth Factors:
- Increasing prevalence of chronic diseases: The global prevalence of chronic diseases is increasing at an alarming rate. This is primarily because of the changing lifestyles and dietary habits of people across the world. Chronic diseases are characterized by long-term symptoms and require lifelong treatment. As a result, there is a growing demand for effective and affordable therapies for these conditions. Antibody drugs offer an efficient and cost-effective solution for the treatment of chronic diseases, which is likely to drive their growth in the coming years.
- Technological advancements: The field of antibody drug development has witnessed significant technological advancements in recent years, thanks to advances in biotechnology and genomics research. These technological advances have helped improve our understanding of how antibodies work and have led to the development of novel antibody drugs with improved efficacy and safety profiles. This is likely to boost demand for antibody drugs in the coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Antibody Drugs Market Research Report
By Type
Monoclonal Antibodies, Antibody-Drug Conjugates, Polyclonal Antibodies
By Application
Central Nervous System (CNS) Disorders, Cancers, Autoimmune Disorders, Cardiovascular Diseases
By Companies
Novartis, Amgen, Bristol-Myers Squibb, F. Hoffmann-La Roche, Johnson & Johnson, AbbVie, Eli Lilly, Pfizer, Bayer, GlaxoSmithKline, Sanofi
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
244
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Antibody Drugs Market Report Segments:
The global Antibody Drugs market is segmented on the basis of:
Types
Monoclonal Antibodies, Antibody-Drug Conjugates, Polyclonal Antibodies
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Central Nervous System (CNS) Disorders, Cancers, Autoimmune Disorders, Cardiovascular Diseases
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Amgen
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- Johnson & Johnson
- AbbVie
- Eli Lilly
- Pfizer
- Bayer
- GlaxoSmithKline
- Sanofi
Highlights of The Antibody Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Monoclonal Antibodies
- Antibody-Drug Conjugates
- Polyclonal Antibodies
- By Application:
- Central Nervous System (CNS) Disorders
- Cancers
- Autoimmune Disorders
- Cardiovascular Diseases
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Antibody Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Antibody drugs are medications that are designed to block the action of specific antibodies.
Some of the major companies in the antibody drugs market are Novartis, Amgen, Bristol-Myers Squibb, F. Hoffmann-La Roche, Johnson & Johnson, AbbVie, Eli Lilly, Pfizer, Bayer, GlaxoSmithKline, Sanofi.
The antibody drugs market is expected to register a CAGR of 10.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Antibody Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Antibody Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Antibody Drugs Market - Supply Chain
4.5. Global Antibody Drugs Market Forecast
4.5.1. Antibody Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Antibody Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Antibody Drugs Market Absolute $ Opportunity
5. Global Antibody Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Antibody Drugs Market Size and Volume Forecast by Type
5.3.1. Monoclonal Antibodies
5.3.2. Antibody-Drug Conjugates
5.3.3. Polyclonal Antibodies
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Antibody Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Antibody Drugs Market Size and Volume Forecast by Application
6.3.1. Central Nervous System (CNS) Disorders
6.3.2. Cancers
6.3.3. Autoimmune Disorders
6.3.4. Cardiovascular Diseases
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Antibody Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Antibody Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Antibody Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Antibody Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Antibody Drugs Demand Share Forecast, 2019-2026
9. North America Antibody Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Antibody Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Antibody Drugs Market Size and Volume Forecast by Application
9.4.1. Central Nervous System (CNS) Disorders
9.4.2. Cancers
9.4.3. Autoimmune Disorders
9.4.4. Cardiovascular Diseases
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Antibody Drugs Market Size and Volume Forecast by Type
9.7.1. Monoclonal Antibodies
9.7.2. Antibody-Drug Conjugates
9.7.3. Polyclonal Antibodies
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Antibody Drugs Demand Share Forecast, 2019-2026
10. Latin America Antibody Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Antibody Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Antibody Drugs Market Size and Volume Forecast by Application
10.4.1. Central Nervous System (CNS) Disorders
10.4.2. Cancers
10.4.3. Autoimmune Disorders
10.4.4. Cardiovascular Diseases
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Antibody Drugs Market Size and Volume Forecast by Type
10.7.1. Monoclonal Antibodies
10.7.2. Antibody-Drug Conjugates
10.7.3. Polyclonal Antibodies
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Antibody Drugs Demand Share Forecast, 2019-2026
11. Europe Antibody Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Antibody Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Antibody Drugs Market Size and Volume Forecast by Application
11.4.1. Central Nervous System (CNS) Disorders
11.4.2. Cancers
11.4.3. Autoimmune Disorders
11.4.4. Cardiovascular Diseases
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Antibody Drugs Market Size and Volume Forecast by Type
11.7.1. Monoclonal Antibodies
11.7.2. Antibody-Drug Conjugates
11.7.3. Polyclonal Antibodies
11.8. Basis Point Shar (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Antibody Drugs Demand Share, 2019-2026
12. Asia Pacific Antibody Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Antibody Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Antibody Drugs Market Size and Volume Forecast by Application
12.4.1. Central Nervous System (CNS) Disorders
12.4.2. Cancers
12.4.3. Autoimmune Disorders
12.4.4. Cardiovascular Diseases
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Antibody Drugs Market Size and Volume Forecast by Type
12.7.1. Monoclonal Antibodies
12.7.2. Antibody-Drug Conjugates
12.7.3. Polyclonal Antibodies
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Antibody Drugs Demand Share, 2019-2026
13. Middle East & Africa Antibody Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Antibody Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Antibody Drugs Market Size and Volume Forecast by Application
13.4.1. Central Nervous System (CNS) Disorders
13.4.2. Cancers
13.4.3. Autoimmune Disorders
13.4.4. Cardiovascular Diseases
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Antibody Drugs Market Size and Volume Forecast by Type
13.7.1. Monoclonal Antibodies
13.7.2. Antibody-Drug Conjugates
13.7.3. Polyclonal Antibodies
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Antibody Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Antibody Drugs Market: Market Share Analysis
14.2. Antibody Drugs Distributors and Customers
14.3. Antibody Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Novartis
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Amgen
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Bristol-Myers Squibb
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. F. Hoffmann-La Roche
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Johnson & Johnson
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. AbbVie
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Eli Lilly
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Pfizer
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Bayer
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. GlaxoSmithKline
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Sanofi
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
